Clinical trials: Epilepsy (Treatment Refractory)
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Refractory Epilepsy
Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy
The purpose of the study is to examine the clinical safety, tolerability, and efficacy of clobazam (Onfi) when it replaces the pre-existing clonazepam therapy in patients with refractory epilepsy.
- Trial name
- NCT01932502
- Testing
- clobazam (Onfi), Initial conversion and titration, Conversion schedule - Week 1
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Epilepsy, Drug Resistant
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive…
- Trial name
- NCT07095933
- Testing
- Everolimus
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xuanwu Hospital, Beijing
Anxiety, Epilepsy
Epidiolex® for Anxiety in Pediatric Epilepsy
This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult…
- Trial name
- NCT05324449
- Testing
- Cannabidiol 100 MG/ML
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Epilepsy
Dietary Therapy in Children With Refractory Epilepsy
In children aged 1yr -18 years with refractory epilepsy Modified Atkins diet as add on to ongoing AED therapy would not be inferior compared to ketogenic diet ** in terms of seizure reduction from baseline seizure frequency at 6…
- Trial name
- NCT01983163
- Testing
- Ketogenic diet (2.5 to 4:1), Modified Atkin's diet
- Where
- India
- Volunteers
- 30 people
- Sponsor
- All India Institute of Medical Sciences
Epilepsy, Partial
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152503
- Testing
- Seletracetam (UCB44212)
- Where
- 17 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- UCB Pharma SA
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
- Trial name
- NCT04457687
- Testing
- Lorcaserin
- Where
- 22 sites in United States, Canada
- Sponsor
- Eisai Inc.
Refractory Epilepsy
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
One third of children with epilepsy have seizures that are medically intractable. Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and cognitive impairment.
- Trial name
- SMAD (NCT01899898)
- Testing
- Simplified Modified Atkins Diet, Antiepileptic drugs alone
- Where
- India
- Volunteers
- 81 people
- Sponsor
- Lady Hardinge Medical College
Epilepsy
Cannabinoid Therapy for Pediatric Epilepsy
This is a Phase 1 trial to determine the tolerability and optimal dose of CBD rich cannabis extract as an adjunct treatment in children with severe drug resistant epilepsy due to Dravet Syndrome.
- Trial name
- NCT02983695
- Testing
- TIL-TC150
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Epilepsy
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy
High-Definition transcranial Direct Current Stimulation (HD tDCS) Genuine cathodal HD-tDCS will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the…
- Trial name
- HD-TDCS (NCT02264652)
- Testing
- HD Transcranial Direct Stimulation
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.
The purpose of this study is to evaluate the effectiveness and safety of topiramate as an add-on therapy in patients with uncontrolled partial onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236847
- Testing
- topiramate
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a…
- Trial name
- NCT00957372
- Testing
- eslicarbazepine acetate, ESL - Open-label Extension (Part II)
- Where
- Portugal
- Volunteers
- 253 people
- Sponsor
- Bial - Portela C S.A.
Refractory Epilepsy, SYNGAP1 Encephalopathy
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
This study is a pilot non-controlled clinical trial with adjunctive fenfluramine for the treatment of five different types of developmental and epileptic encephalopathies (DEEs) focused on epileptic and "non-epileptic outcomes"…
- Conditions
- Refractory Epilepsy, SYNGAP1 Encephalopathy, STXBP1 Encephalopathy With Epilepsy, Inv Dup(15) Encephalopathy
- Trial name
- FENDEEP (NCT05232630)
- Testing
- Fenfluramine
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Ruber Internacional
Refractory Partial Seizures
Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.
- Trial name
- NCT04558580
- Testing
- Rufinamide
- Where
- United States
- Sponsor
- University of South Alabama
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Epilepsy, Temporal Lobe
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes…
- Trial name
- NCT06422923
- Testing
- NRTX-1001
- Where
- 17 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neurona Therapeutics
Epilepsy, Lennox Gastaut Syndrome
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or…
- Conditions
- Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
- Trial name
- NCT05339126
- Testing
- RNS System
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- NeuroPace
Epilepsy
Safety of Autologous MSC Infusion to Treat Epilepsy
The goal of this study was to evaluate the safety and efficacy of autologous MSC application for the therapy of drug-resistant symptomatic epilepsy.
- Trial name
- AMSCDRSE (NCT02497443)
- Testing
- Autologous mesenchymal stem cells
- Volunteers
- 60 people
- Sponsor
- Ministry of Public Health, Republic of Belarus
Epileptic Seizure, Epilepsy Intractable
REC2Stim as a Treatment for Refractory Epilepsy in the Primary Sensorimotor Cortex.
People with central lobe epilepsy (CLE), with seizures arising from the primary sensorimotor cortex, typically show a high rate of convulsive seizures that do not respond to anti-epileptic drugs, but have a large impact on…
- Conditions
- Epileptic Seizure, Epilepsy Intractable, Motor Seizure
- Trial name
- REC2Stim (NCT04158531)
- Testing
- ECoG sensing and stimulation
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- UMC Utrecht
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of the study is to evaluate the efficacy and safety of topiramate in epilepsy patients with difficult to treat, partial-onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236873
- Testing
- topiramate
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.